Physician profile
Peter Nicholas
NPI 1730185505
$5,753.00
in general payments reported to CMS, 2019-2025
23 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,679 · 2020: $228 · 2021: $165 · 2022: $321 · 2023: $907 · 2024: $1,049 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.16 |
| Education | $194.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.26 | 2019-2025 | |
| Amgen INC. | $754.84 | 2019-2025 | Tavneos, Evenity, Uplizna |
| Novartis Pharmaceuticals Corporation | $698.50 | 2019-2025 | |
| Janssen Biotech, INC. | $651.37 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $644.36 | 2021-2025 | Saphnelo |
| Ucb, INC. | $631.92 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $322.15 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $272.34 | 2019-2024 | Actemra |
| Pfizer INC. | $254.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $221.14 | 2019-2024 | Orencia |
| Horizon Therapeutics Plc | $99.85 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $84.81 | 2019-2025 | |
| Lilly USA, LLC | $71.34 | 2019-2025 | Taltz |
| Medexus Pharma, INC. | $55.07 | 2019 | |
| Ani Pharmaceuticals, INC. | $46.50 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34.51 | 2024 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $28.25 | 2025 | Simlandi |
| Organon LLC | $28.00 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $21.09 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.04 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $19.44 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $15.61 | 2019 | |
| Celgene Corporation | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nicholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.